Secondary Prevention of Venous Thromboembolism: One Regimen May Not Fit All.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya.Clinical drug investigation · 2025
   Article
2. Preventing Postpartum Venous Thromboembolism in 2022: A Narrative Review.Frontiers in cardiovascular medicine · 2022
   Review
3. Supportive medication in cancer during pregnancy.BMC pregnancy and childbirth · 2020
   Review
4. Extended anticoagulation after venous thromboembolism: should it be done?Therapeutic advances in respiratory disease
   Review

Corrections and comments

• Comment on
  Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.2015

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as